Core Viewpoint - The stock of Baiaosaitu-B (02315) has risen over 10% following the announcement of a collaboration with Merck to develop antibody-conjugated lipid delivery solutions for nucleic acid drugs [1] Group 1: Company Developments - Baiaosaitu has signed an evaluation agreement with Merck for antibody selection rights, focusing on the development of antibody-conjugated lipid nanoparticles (LNP) [1] - The agreement allows Merck to evaluate the feasibility of using Baiaosaitu's fully human antibodies, developed on its RenMice platform, for LNP formulation services [1] - Baiaosaitu is entitled to receive corresponding fee payments, sales shares, and sublicensing shares from Merck [1] Group 2: Research and Development Initiatives - The company is conducting large-scale drug development targeting over 1,000 potential druggable targets under its "Thousand Mice, Ten Thousand Antibodies" program [1] - Baiaosaitu has established a library of over 1 million fully human antibody sequences for global collaborations [1] - As of June 30, 2025, Baiaosaitu has signed approximately 280 drug collaboration/development/transfer agreements and has engaged in over 50 target projects for RenMice platform development with multiple multinational corporations [1]
港股异动 | 百奥赛图-B(02315)涨超10% 与默克签署抗体选择权评估协议 推进抗体偶联脂质递送解决方案